Bristol-Myers Squibb Files First BPCIA Suit Over Opdivo Biosimilar

Bristol-Myers Squibb has initiated the first patent infringement litigation under the BPCIA against Amgen over its proposed biosimilar to the blockbuster cancer drug Opdivo®.